Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer

BACKGROUND: Although the Decipher genomic classifier has been validated as a prognostic tool for several prostate cancer endpoints, little is known about its role in assessing the risk of biopsy reclassification for patients on active surveillance, a key event that often triggers treatment. OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales: Press, Benjamin H., Jones, Tashzna, Olawoyin, Olamide, Lokeshwar, Soum D., Rahman, Syed N., Khajir, Ghazal, Lin, Daniel W., Cooperberg, Matthew R., Loeb, Stacy, Darst, Burcu F., Zheng, Yingye, Chen, Ronald C., Witte, John S., Seibert, Tyler M., Catalona, William J., Leapman, Michael S., Sprenkle, Preston C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883188/
https://www.ncbi.nlm.nih.gov/pubmed/35243396
http://dx.doi.org/10.1016/j.euros.2022.01.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883188/
https://www.ncbi.nlm.nih.gov/pubmed/35243396
http://dx.doi.org/10.1016/j.euros.2022.01.008

Ejemplares similares